He Liru, Chapple Andrew, Liao Zhongxing, Komaki Ritsuko, Thall Peter F, Lin Steven H
Department of Radiation Oncology, Sun Yat-Sun University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Department of Statistics, Rice University, Houston, USA.
Radiother Oncol. 2016 Oct;121(1):70-74. doi: 10.1016/j.radonc.2016.08.005. Epub 2016 Aug 22.
To evaluate radiation modality effects on pericardial effusion (PCE), pleural effusion (PE) and survival in esophageal cancer (EC) patients.
We analyzed data from 470 EC patients treated with definitive concurrent chemoradiotherapy (CRT). Bayesian semi-competing risks (SCR) regression models were fit to assess effects of radiation modality and prognostic covariates on the risks of PCE and PE, and death either with or without these preceding events. Bayesian piecewise exponential regression models were fit for overall survival, the time to PCE or death, and the time to PE or death. All models included propensity score as a covariate to correct for potential selection bias.
Median times to onset of PCE and PE after RT were 7.1 and 6.1months for IMRT, and 6.5 and 5.4months for 3DCRT, respectively. Compared to 3DCRT, the IMRT group had significantly lower risks of PE, PCE, and death. The respective probabilities of a patient being alive without either PCE or PE at 3-years and 5-years were 0.29 and 0.21 for IMRT compared to 0.13 and 0.08 for 3DCRT. In the SCR regression analyses, IMRT was associated with significantly lower risks of PCE (HR=0.26) and PE (HR=0.49), and greater overall survival (probability of beneficial effect (pbe)>0.99), after controlling for known clinical prognostic factors.
IMRT reduces the incidence and postpones the onset of PCE and PE, and increases survival probability, compared to 3DCRT.
评估放疗方式对食管癌(EC)患者心包积液(PCE)、胸腔积液(PE)及生存的影响。
我们分析了470例接受根治性同步放化疗(CRT)的EC患者的数据。采用贝叶斯半竞争风险(SCR)回归模型评估放疗方式和预后协变量对PCE和PE风险以及有无这些前驱事件时死亡风险的影响。采用贝叶斯分段指数回归模型分析总生存、出现PCE或死亡的时间以及出现PE或死亡的时间。所有模型均将倾向得分作为协变量纳入以校正潜在的选择偏倚。
调强放疗(IMRT)后PCE和PE发生的中位时间分别为7.1个月和6.1个月,三维适形放疗(3DCRT)后分别为6.5个月和5.4个月。与3DCRT相比,IMRT组发生PE、PCE及死亡的风险显著更低。IMRT组患者3年和5年时无PCE或PE存活的概率分别为0.29和0.21,而3DCRT组分别为0.13和0.08。在SCR回归分析中,在控制已知临床预后因素后,IMRT与PCE(风险比[HR]=0.26)和PE(HR=0.49)风险显著降低以及更高的总生存(有益效应概率[pbe]>0.99)相关。
与3DCRT相比,IMRT可降低PCE和PE的发生率,推迟其发生时间,并提高生存概率。